New equity awards for BioNTech (NASDAQ: BNTX) Chief People Officer

Rhea-AI Filing Summary

BioNTech SE reported that Chief People Officer Kylie Jimenez received new equity-based compensation. She was granted 8,391 performance share units, each economically equivalent to one ordinary share, and options over 10,488 ordinary shares.

The performance share units and options both vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to performance-based and other conditions. The option has an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, and/or cash at the supervisory board’s election.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Jimenez Kylie

Role Chief People Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	10,488	$0.00	--
Grant/Award	Performance Share Unit	8,391	$0.00	--

Holdings After Transaction: Option (right to buy) — 10,488 shares (Direct, null); Performance Share Unit — 8,391 shares (Direct, null)

Footnotes (1)

1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Key Figures

Performance share units granted: 8,391 units Options granted: 10,488 options Option exercise price: EUR 89.38 per share +3 more

6 metrics

Performance share units granted 8,391 units Grant to Chief People Officer Kylie Jimenez

Options granted 10,488 options Right to buy ordinary shares

Option exercise price EUR 89.38 per share Exercise price for granted options

PSU-to-share ratio 1 PSU : 1 share Each PSU equals one ordinary share economically

Vesting period 4 years Annual installments starting on first anniversary of grant

Option exercisability After 4 years Becomes exercisable four years after grant date

Key Terms

Performance Share Unit, American Depositary Share, Nasdaq Biotechnology Index, exercise price, +1 more

5 terms

Performance Share Unit financial

"Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer"

A performance share unit (PSU) is a form of executive or employee pay that promises shares (or the cash value of shares) only if the company meets specific performance targets over a set period. Think of it like a bonus cheque that only arrives if the company hits agreed goals — it aligns managers’ rewards with business results and signals to investors how leadership is being incentivized to grow value over time.

American Depositary Share financial

"the trading price of an American Depositary Share ("ADS") as of an exercise date"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Nasdaq Biotechnology Index financial

"based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index"

A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.

exercise price financial

"The exercise price of this option is EUR 89.38."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

performance-based conditions financial

"subject to certain performance-based and other conditions."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jimenez Kylie

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	05/12/2026		A		10,488		05/12/2030(2)	05/12/2036	Ordinary Shares(3)	10,488	$0	10,488	D
Performance Share Unit	$0	05/12/2026		A		8,391		05/12/2030(4)	05/12/2036	Ordinary Shares(4)	8,391	$0	8,391	D

Explanation of Responses:

1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

2. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

3. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

4. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Remarks:

	/s/ Humza Bokhari, Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did BioNTech (BNTX) grant to Kylie Jimenez?

BioNTech granted Kylie Jimenez 8,391 performance share units and options over 10,488 ordinary shares. Both awards are part of her compensation package and are tied to multi-year vesting and performance conditions.

How do the BioNTech (BNTX) performance share units for Kylie Jimenez work?

Each performance share unit equals one ordinary share’s economic value and may settle in shares, ADSs, or cash. The units vest annually over four years and depend on market-based performance targets and continued service.

What are the key terms of the stock options granted by BioNTech (BNTX)?

The options cover 10,488 ordinary shares with an exercise price of EUR 89.38. They vest in equal annual installments over four years and become exercisable four years after grant, subject to performance and other conditions.

When do Kylie Jimenez’s new BioNTech (BNTX) equity awards vest and become exercisable?

Both the performance share units and options vest annually in equal installments over four years, starting on the first anniversary of grant. They become exercisable four years after the grant date, subject to meeting specified conditions.

Can BioNTech (BNTX) settle these performance share units and options in cash?

Yes. The filing states the option and performance share units may be settled in ordinary shares, ADSs, and/or cash. The supervisory board or issuer can choose the settlement form according to the plan’s terms.

Are BioNTech (BNTX) performance targets tied to any index for these PSUs?

Yes. The performance share units depend on share price performance relative to the Nasdaq Biotechnology Index or a comparable successor index, along with the reporting person’s continued service through the vesting dates.